SLT 0.00% 0.7¢ select exploration limited

select vaccines - on the rise

  1. 280 Posts.
    Up 3.2% today, selling pressure as eased off quite a bit.


    Board & Management
    ----------------------
    Dr Martin Soust BSc (Hons) MBA PhD
    Managing Director (Age 42)
    Dr Soust has had a career in medical research and small/medium sized enterprise management.

    Mr Peter Marks BEc LLB Grad. Dip. Comm. Law MBA
    Executive Director (Age 47)
    Mr Marks has extensive experience in the areas of the provision of corporate advice as well as corporate finance and venture capital investment..

    Mr Jeremy Cooper BA MBA
    Finance Director (Age 36)
    Mr Cooper has 14 years experience in senior management positions with major international corporations, focussing on strategy, business development and mergers and acquisitions.

    Mr George Weber
    Non-Executive Director
    George Weber has a strong background in the commercialisation of life sciences. Originally from the United States, Mr. Weber worked with Eli Lilly and Johnson & Johnson in a variety of sales and management functions that included responsibility for the management functions that included responsibility for the marketing and sales of pharmaceutical, instrumentation, implant and diagnostic products. The latter included responsibility for Hepatitis C tests marketed by Ortho Diagnostics (a division of Johnson & Johnson) in conjunction with Chiron Inc.

    Dr Ian Cooke
    Non-Executive Director
    Dr Ian Cooke is Associate Director (Research and Development) at the Macfarlane Burnet Institute for Medial Research and Public Health Ltd in Melbourne. He is responsible for the overall management of the Burnet Institute’s major research activities, with a particular focus on the commercialisation of emerging technologies developed by the Institute’s scientists.

    Dr David Anderson BSc (Hons) PhD (Melbourne)
    Chief Scientific Officer - Hepgenics and Picoral (Age 42)
    Dr David Anderson is Deputy Director of the Macfarlane Burnet Institute for Medical Research and Public Health, and a Senior Research Fellow of the National Health and Medical Research Council.

    Thats all of them.


    No Bryan Frost....


    Also Martin Soust was quoted saying on the 10/07/03 regarding rapid diagnostic kit for testing hepatitis.

    "MARTIN SOUST, MD, SELECT VACCINES:
    We're confident we can get them into the marketplace within 12 months through a manufacturer and distributor, who we would licence that technology to."

    He was fairly close to mark when he said 12 months.
    It has been about 13 months - July 2003 to August 2004.



    Cheers,
    Ace.


 
watchlist Created with Sketch. Add SLT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.